Pyxis Oncology (PYXS) Asset Utilization Ratio (2024 - 2025)
Pyxis Oncology (PYXS) reported Asset Utilization Ratio of 0.14 for Q4 2025, up 53.48% year-over-year from 0.09 in Q4 2024, and up 470.43% quarter-over-quarter from 0.02 in Q3 2025.
Pyxis Oncology (PYXS) Asset Utilization Ratio (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of Asset Utilization Ratio data on file, last reported at 0.14 in Q4 2025.
- Asset Utilization Ratio for Q4 2025 came in at 0.14, up 53.48% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.14 (up 53.48% YoY), and the FY2025 annual result was 0.11, up 14.2% from the prior year.
- Asset Utilization Ratio grew to 0.14 in Q4 2025 per PYXS's latest filing, from 0.02 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.14 in Q4 2025 and troughed at 0.02 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | 0.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.14 |
| Sep 30, 2025 | 0.02 |
| Jun 30, 2025 | 0.02 |
| Dec 31, 2024 | 0.09 |